- Home
- RCS vs ANGO Comparison
RCS vs ANGO Comparison
Compare RCS & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- ANGO
- Stock Information
- Founded
- RCS 1994
- ANGO 1988
- Country
- RCS United States
- ANGO United States
- Employees
- RCS N/A
- ANGO N/A
- Industry
- RCS Investment Managers
- ANGO Medical/Dental Instruments
- Sector
- RCS Finance
- ANGO Health Care
- Exchange
- RCS Nasdaq
- ANGO Nasdaq
- Market Cap
- RCS 296.3M
- ANGO 400.8M
- IPO Year
- RCS N/A
- ANGO 2004
- Fundamental
- Price
- RCS $7.09
- ANGO $9.33
- Analyst Decision
- RCS
- ANGO Strong Buy
- Analyst Count
- RCS 0
- ANGO 2
- Target Price
- RCS N/A
- ANGO $15.50
- AVG Volume (30 Days)
- RCS 141.1K
- ANGO 570.7K
- Earning Date
- RCS 01-01-0001
- ANGO 07-15-2025
- Dividend Yield
- RCS 10.12%
- ANGO N/A
- EPS Growth
- RCS N/A
- ANGO N/A
- EPS
- RCS N/A
- ANGO N/A
- Revenue
- RCS N/A
- ANGO $283,320,000.00
- Revenue This Year
- RCS N/A
- ANGO N/A
- Revenue Next Year
- RCS N/A
- ANGO $6.35
- P/E Ratio
- RCS N/A
- ANGO N/A
- Revenue Growth
- RCS N/A
- ANGO N/A
- 52 Week Low
- RCS $4.51
- ANGO $5.67
- 52 Week High
- RCS $6.31
- ANGO $13.50
- Technical
- Relative Strength Index (RSI)
- RCS 68.31
- ANGO 43.45
- Support Level
- RCS $7.00
- ANGO $9.12
- Resistance Level
- RCS $7.16
- ANGO $9.78
- Average True Range (ATR)
- RCS 0.07
- ANGO 0.40
- MACD
- RCS -0.01
- ANGO -0.09
- Stochastic Oscillator
- RCS 80.26
- ANGO 26.24
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.